Effect of Spironolactone nano-emulgel on acne
- Conditions
- Acne vulgaris.Acne vulgaris
- Registration Number
- IRCT2015051010203N6
- Lead Sponsor
- Vice chancellor of research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
patients with mild to moderate acne, defined as a score of 1 to 30 on the global acne grading system (GAGS) scale, who were not satisfied with their previous acne therapies participated in the study after giving written informed consent
Exclusioncriteria: Patients were excluded if they had an uncontrolled systemic disease; had received topical antiacne therapy two months before or during the study or any systemic therapy with antibiotics, OCP, and spironolactone 30 days before or during the study; were known to be allergic or sensitive to any of the study medications or their components; had previously been treated with systemic retinoids; had a skin disease that might interfere with the diagnosis or evaluation of their hyperpigmentation; or were pregnant, or planning to become pregnant, and lactating.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Skin lesion. Timepoint: 0, 4, and 8 weeks. Method of measurement: observation.
- Secondary Outcome Measures
Name Time Method Sebum excretion. Timepoint: 0, 4, 8 weeks. Method of measurement: sebometer.